Xenon Halts Trial Enrollment After Adverse Events
By Katherine Hamilton
Xenon Pharmaceuticals said it was voluntarily pausing enrollment for trials of azetukalner to treat depression and bipolar treatments, after adverse events occurred in the studies.
The biopharmaceutical company said the pause is a precaution while Xenon is in consultation with its data safety monitoring board. The participants already enrolled in the studies will continue.
Xenon's stock sank 20% to $45.98 in after-hours trading Thursday. Through the close, shares were up 29% this year.
The company said the observed events, as well as their rate and severity, were consistent with the known safety and tolerability profile of azetukalner, but the events hadn't previously been seen in an earlier trial.
Xenon expects the pause to be temporary and is evaluating different dosing modifications to help mitigate adverse events.
Azetukalner is also being evaluated as a treatment for seizures. Xenon said Thursday that it submitted a new drug application to the Food and Drug Administration for azetukalner as a treatment for focal seizures.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
September 17, 2026 16:39 ET (20:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States